


## Supplementary Online Content

Wang SY, Singh K, Stein JD, Chang RT. Ocular antihypertensive medication use after iStent implantation concurrent with cataract surgery vs cataract surgery alone in a large US healthcare claims database. *JAMA Ophthalmol*. Published online September 27, 2018. doi:10.1001/jamaophthalmol.2018.4461

**eFigure.** Number of Topical Antihyperintensive Medications Used at Baseline and Postoperatively Among iStent/CEIOL Cohort

This supplementary material has been provided by the authors to give readers additional information about their work.

**eFigure. Number of topical antihypertensive medications used at baseline and postoperatively among iStent/CEIOL cohort, excluding patients on no topical antihypertensives at baseline**



Legend: Proportions and number of patients on 0, 1, 2, or 3 or more topical antihypertensive agents at baseline and postoperatively are shown for those who underwent bilateral or unilateral iStent implantation with cataract extraction and intraocular lens implantation (iStent/CEIOL). For this sensitivity analysis, patients who were on 0 medications at baseline were excluded. (\*) denotes statistically significant difference from baseline time proportions of agents used (P value <0.0001 for all time points, chi-squared tests). POM = postoperative month.